HUP0001684A2 - Fumársavszármazékok felhasználása - Google Patents

Fumársavszármazékok felhasználása

Info

Publication number
HUP0001684A2
HUP0001684A2 HU0001684A HUP0001684A HUP0001684A2 HU P0001684 A2 HUP0001684 A2 HU P0001684A2 HU 0001684 A HU0001684 A HU 0001684A HU P0001684 A HUP0001684 A HU P0001684A HU P0001684 A2 HUP0001684 A2 HU P0001684A2
Authority
HU
Hungary
Prior art keywords
general formula
mixed
cation
graves
grass
Prior art date
Application number
HU0001684A
Other languages
English (en)
Inventor
Rajendra K. Joshi
Hans-Peter Strebel
Original Assignee
Fumapharm Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fumapharm Ag. filed Critical Fumapharm Ag.
Publication of HUP0001684A2 publication Critical patent/HUP0001684A2/hu
Publication of HUP0001684A3 publication Critical patent/HUP0001684A3/hu
Publication of HU227697B1 publication Critical patent/HU227697B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/593—Dicarboxylic acid esters having only one carbon-to-carbon double bond
    • C07C69/60—Maleic acid esters; Fumaric acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A jelen találmány tárgya egy vagy több vegyület alkalmazása az (I)általánős képletű fűmársav-mőnőalkil-észterek kalciűm-, magnéziűm-,cink-, és vas-sóiból, tetszés szerint (II) általánős képletű dialkil-fűmaráttal keverve, ahől az A általánős képletű csőpőrt a kalciűm,magnéziűm, cink vagy vas két vegyértékű katiőnja, illetve a káliűmvagy a nátriűm egyvegyértékű katiőnja, az n egész szám értéke pedig 1vagy 2 a katiőn típűsától függően, vagy egy vagy több vegyületalkalmazása (III) általánős képletű alkil-hidrőgén-fűmarátők közül,tetszés szerint (II) általánős képletű dialkil-fűmaráttal, illetvetetszés szerint közönségesen használt gyógyászati töltő- ésvivőanyagőkkal keverve, pőlyarthritis, Scleőrősis műltiplex,kilökődési reakciók, fiatalkőri diabetes, Hashimőtő-Thyreőditis,Grave-betegség (Graves- vagy Basedőw-kór), szisztémás Lűpűserythematődes (SLE), Sjörgen-szindróma, vészes anémia vagy krónikűsaktív (lűpőid) hepatitis kezelésére alkalmas gyógyszerkészítményelőállítására. ŕ
HU0001684A 1997-05-20 1998-04-01 Use of fumaric acid derivatives for preparation of medicaments for treating autoimmune diseases HU227697B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19721099A DE19721099C2 (de) 1997-05-20 1997-05-20 Verwendung von Fumarsäurederivaten
PCT/EP1998/001894 WO1998052549A2 (de) 1997-05-20 1998-04-01 Verwendung von fumarsäurederivaten

Publications (3)

Publication Number Publication Date
HUP0001684A2 true HUP0001684A2 (hu) 2000-09-28
HUP0001684A3 HUP0001684A3 (en) 2001-09-28
HU227697B1 HU227697B1 (en) 2011-12-28

Family

ID=7829995

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0001684A HU227697B1 (en) 1997-05-20 1998-04-01 Use of fumaric acid derivatives for preparation of medicaments for treating autoimmune diseases

Country Status (25)

Country Link
US (1) US6436992B1 (hu)
EP (1) EP0980242B1 (hu)
JP (1) JP3881038B2 (hu)
CN (1) CN1153569C (hu)
AT (1) ATE232093T1 (hu)
AU (1) AU730441B2 (hu)
BG (1) BG64613B1 (hu)
BR (1) BR9809655A (hu)
CA (1) CA2248955C (hu)
CZ (1) CZ299960B6 (hu)
DE (2) DE19721099C2 (hu)
DK (1) DK0980242T3 (hu)
EE (1) EE03999B1 (hu)
ES (1) ES2190588T3 (hu)
HK (1) HK1027512A1 (hu)
HU (1) HU227697B1 (hu)
IL (1) IL132819A (hu)
NO (1) NO326815B1 (hu)
NZ (1) NZ501755A (hu)
PL (1) PL190864B1 (hu)
RS (1) RS49654B (hu)
RU (1) RU2197963C2 (hu)
SK (1) SK285897B6 (hu)
TR (1) TR199902587T2 (hu)
WO (1) WO1998052549A2 (hu)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) * 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10000577A1 (de) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
PL392750A1 (pl) * 2001-01-12 2011-05-23 Fumapharm Ag Amidy kwasu fumarowego
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
DE10217314A1 (de) * 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
DE10360869A1 (de) * 2003-09-09 2005-04-07 Fumapharm Ag Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
PL1663197T3 (pl) * 2003-09-09 2008-09-30 Biogen Idec Int Gmbh Zastosowanie pochodnych kwasu fumarowego do leczenia niewydolności serca oraz astmy
HUP0303779A2 (en) * 2003-11-20 2006-02-28 Richter Gedeon Vegyeszet Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex
DE202005022112U1 (de) * 2004-10-08 2014-04-24 Forward Pharma A/S Pharmazeutische Zusammensetzungen mit kontrollierter Freisetzung, umfassend einen Fumarsaureester
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
US20070142905A1 (en) * 2005-12-16 2007-06-21 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
WO2007148744A1 (ja) * 2006-06-21 2007-12-27 Santen Pharmaceutical Co., Ltd. フマル酸誘導体を有効成分として含む角結膜障害の予防または治療剤
WO2008096271A2 (en) * 2007-02-08 2008-08-14 Ralf Gold Neuroprotection in demyelinating diseases
EP4137819A1 (en) 2007-02-08 2023-02-22 Biogen MA Inc. Compositions and uses for treating multiple sclerosis
EP2334378B1 (en) 2008-08-19 2014-04-09 XenoPort, Inc. Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
RU2743637C2 (ru) 2009-01-09 2021-02-20 Фвп Ип Апс Фармацевтический состав, содержащий один или более эфиров фумаровой кислоты в разлагаемой матрице
CA2760133A1 (en) 2009-04-29 2010-11-04 Biogen Idec Ma Inc. Treatment of neurodegeneration and neuroinflammation
ME02317B (me) * 2010-02-12 2016-06-20 Biogen Ma Inc Neuroprotekcija kod demijelinizacijskih bolesti
PE20141316A1 (es) * 2011-05-26 2014-10-01 Biogen Idec Inc Metodos para tratar la esclerosis multiple y preservar y/o aumentar el contenido de mielina
RS56972B1 (sr) 2011-06-08 2018-05-31 Biogen Ma Inc Postupak za pripremu visoko-čistog i kristalnog dimetil fumarata
EP2782561A1 (en) 2011-11-24 2014-10-01 Synthon BV Controlled release particles comprising dimethyl fumarate
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
AU2013203445C1 (en) 2012-02-07 2017-04-20 Biogen Ma Inc. Pharmaceutical compositions containing dimethyl fumarate
NZ629728A (en) 2012-02-07 2016-07-29 Xenoport Inc Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use
CA2882713A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
EP2887933A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
US20140171504A1 (en) 2012-12-14 2014-06-19 Georgia Regents Research Institute, Inc. Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
ES2733961T3 (es) 2012-12-21 2019-12-03 Biogen Ma Inc Derivados de fumarato sustituidos con deuterio
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
RS57497B1 (sr) 2013-03-14 2018-10-31 Alkermes Pharma Ireland Ltd Prolekovi fumarata i njihova upotreba u lečenju raznih bolesti
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
CN104415026A (zh) * 2013-08-31 2015-03-18 成都渊源生物科技有限公司 氘代富马酸衍生物在治疗多发性硬化症中的应用
EP3041467A1 (en) 2013-09-06 2016-07-13 XenoPort, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
AU2015218587B2 (en) 2014-02-24 2017-04-27 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326965B2 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
DE102014010832A1 (de) 2014-07-24 2016-01-28 Peter Krause Verwendung von medikamentösen Ingredienzien zur Behandlung von Multiple Sklerose
AU2015328676B2 (en) * 2014-10-08 2017-07-20 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
WO2016074684A1 (en) 2014-11-11 2016-05-19 Syddansk Universitet Fumaric acid derivatives for medical use
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
WO2016090154A1 (en) 2014-12-04 2016-06-09 Biogen Ma Inc. Multiple sclerosis treatment regimen using dimethyl fumarate
CN107847451A (zh) * 2015-02-02 2018-03-27 英仕柏集团有限责任公司 稳定的富马酸二烷基酯组合物
HUE055210T2 (hu) 2015-02-08 2021-11-29 Alkermes Pharma Ireland Ltd Monometilfumarát prodrug készítmények
MA41785A (fr) 2015-03-20 2018-01-23 Biogen Ma Inc Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
ES2826825T3 (es) 2015-03-27 2021-05-19 Symbionyx Pharmaceuticals Inc Composiciones y métodos para el tratamiento de la psoriasis
US10213411B2 (en) 2015-08-27 2019-02-26 Vijaykumar Rajasekhar Use of prodrugs of fumarates in treating heart failure diseases
WO2017060400A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
US10463642B2 (en) 2016-02-01 2019-11-05 Vijaykumar Rajasekhar Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
JP2019510743A (ja) * 2016-02-12 2019-04-18 ウニヴェルズィテート チューリッヒ 痛風、ざ瘡及び糖尿病の予防又は治療のためのジメチルフマレート（ｄｍｆ）
CN107973714A (zh) * 2017-12-26 2018-05-01 荆门医药工业技术研究院 一种富马酸单乙酯盐类的制备方法
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
CA3182369A1 (en) 2020-05-06 2021-07-22 Imcyse Sa Combination treatment for fumarate-related diseases
WO2022132978A1 (en) * 2020-12-18 2022-06-23 Upsher-Smith Laboratories, Llc Modified release solid oral dosage form for once daily administration of monomethyl fumarate

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530372A1 (de) * 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2621214C3 (de) * 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
US4346118A (en) * 1980-05-02 1982-08-24 University Of Delaware Antimicrobial agents added to animal feeds
CH664150A5 (de) * 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
DE3531597A1 (de) * 1985-09-04 1987-03-05 Bioferon Biochem Substanz Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur behandlung psoriatischer erkrankungen
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US4768439A (en) * 1987-10-23 1988-09-06 Singer Stewart M Flare composition and flare comprising said composition
IL102236A0 (en) * 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
JPH06345644A (ja) * 1993-06-10 1994-12-20 Unitika Ltd 自己免疫性疾患治療剤
JP3131112B2 (ja) * 1994-02-17 2001-01-31 株式会社資生堂 シクロスポリン含有乳化組成物
JPH07278187A (ja) * 1994-04-07 1995-10-24 Nippon Shinyaku Co Ltd シクロスポリン類のリン酸エステル誘導体及び医薬組成物
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
GB2291422A (en) * 1994-07-18 1996-01-24 Fujisawa Pharmaceutical Co 4-phenyl-pyrido[2,3-b]pyrazin-4-ones
US5763190A (en) 1994-09-21 1998-06-09 The Trustees Of The University Of Pennsylvania Methods for the identification of compounds capable of inducing the nuclear translocation of a receptor complex comprising the glucocoticoid receptor type II and viral protein R interacting protein
CN1125141A (zh) * 1994-12-22 1996-06-26 杭州中美华东制药有限公司 一种含环孢菌素a的固体分散物及其外用剂型上的用途
KR970064620A (ko) * 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물

Also Published As

Publication number Publication date
YU57599A (sh) 2001-12-26
PL335381A1 (en) 2000-04-25
JP3881038B2 (ja) 2007-02-14
BR9809655A (pt) 2000-07-11
BG103335A (en) 2000-04-28
CZ108099A3 (cs) 1999-08-11
WO1998052549A3 (de) 1999-04-08
RS49654B (sr) 2007-09-21
ATE232093T1 (de) 2003-02-15
EE03999B1 (et) 2003-04-15
EP0980242A2 (de) 2000-02-23
SK41599A3 (en) 2000-12-11
HUP0001684A3 (en) 2001-09-28
ES2190588T3 (es) 2003-08-01
JP2000513023A (ja) 2000-10-03
DK0980242T3 (da) 2003-04-14
HU227697B1 (en) 2011-12-28
RU2197963C2 (ru) 2003-02-10
DE19721099A1 (de) 1998-11-26
EP0980242B1 (de) 2003-02-05
CN1257426A (zh) 2000-06-21
CZ299960B6 (cs) 2009-01-07
NO326815B1 (no) 2009-02-23
IL132819A0 (en) 2001-03-19
AU7213698A (en) 1998-12-11
IL132819A (en) 2004-12-15
SK285897B6 (sk) 2007-10-04
PL190864B1 (pl) 2006-02-28
CA2248955A1 (en) 1997-05-20
NO991342L (no) 1999-11-16
HK1027512A1 (en) 2001-01-19
WO1998052549A2 (de) 1998-11-26
CA2248955C (en) 2001-08-14
US6436992B1 (en) 2002-08-20
DE59807122D1 (de) 2003-03-13
CN1153569C (zh) 2004-06-16
NO991342D0 (no) 1999-03-19
DE19721099C2 (de) 1999-12-02
BG64613B1 (bg) 2005-09-30
NZ501755A (en) 2001-07-27
EE9900535A (et) 2000-06-15
TR199902587T2 (xx) 2000-08-21
WO1998052549B1 (de) 1999-05-14
AU730441B2 (en) 2001-03-08

Similar Documents

Publication Publication Date Title
HUP0001684A2 (hu) Fumársavszármazékok felhasználása
ZA895613B (en) Chemical compounds
IL120584A (en) 1,2-diphenylpyrrole derivatives, use thereof for the manufacture of a medicament and pharmaceutical compositions containing the same
HUT43843A (en) Process for production of derivatives of benzimidasole and medical compounds containing thereof
IE861820L (en) 2-hydroxy-2-phenylethylaminotetralines
GR3005990T3 (hu)
GB8809481D0 (en) Chemical compounds
ES8605507A1 (es) Un compuesto de 3-indolcarboxamida
ES2053946T3 (es) Un procedimiento para la preparacion de tetrahidroimidazo(1,4)benzodiazepin-2-onas.
ES8802137A1 (es) Un precedimiento para preparar derivados de ciclopentil-eter
AU5491194A (en) Cytotoxic and antiviral compound
AU7266291A (en) A novel substituted-amine compound and a process for the preparation thereof
KR880009975A (ko) 화합물
EP0270046A3 (en) Pharmaceutical composition for treatment of cataract
NZ222261A (en) Pharmaceutical compositions containing antiinflammatory drugs and cyclopentyl ethers
ES2000681A6 (es) Un procedimiento para preparar nuevos compuestos de bencilpiperazina
NZ215861A (en) Condensed triazole derivatives and pharmaceutical compositions
ES8707951A1 (es) Derivados de tetrazol
DE69535210D1 (de) Pharmazeutische Zusammensetzung enthaltend 2,3-Alkylcarbonyloxybenzoesäure und Ibuprofen
AU1523488A (en) Thiadiazole guanidines
EP0154491A3 (en) Quinate salts of the antimalarial compound mefloquine
EP0284069A3 (en) Benzopyranopyridineacetic acid ester compounds and their pharmaceutical uses
AU572374B2 (en) Azolyl-aroxymethyl-dimethylpentinols, their use as fungicides

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees